Prostate Cancer International is
for 2011 by Great NonProfits
With reference to the need to keep funding high for the Prostate Cancer Research Program (see yesterday’s story), please make sure that you call or write your Congressman or Congresswoman was early as possible TODAY. You have until about 5 pm Eastern time here in the USA to get messages in to your representative asking [...]
Filed under: Uncategorized | Leave a Comment »
The complexity of access to new agents for the treatment of prostate cancer in countries around the world is not necessarily evident to all our readers, so, just as an example, here is the situation as of today regarding access to abiraterone acetate in the UK alone:
Filed under: Uncategorized | 5 Comments »
We are now able to confirm that the full results of the Phase III trial of abiraterone acetate + placebo in the treatment of men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer are being submitted for approval
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: abiraterone, castration-resistant, chemotherapy-naïve, medtaststic | 2 Comments »
For many men, a diagnosis of prostate cancer of any stage or grade — even of the lowest level of risk — is hard to deal with. If they have progressive disease after first-line therapy, it may appear to be an overwhelming issue.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Uncategorized | Tagged: advanced, hope, outcome, survival | 3 Comments »
A new report in the British Journal of Cancer suggests that data provided through Myriad Genetics’ Prolaris™ test may be “the strongest independent predictor of cancer death outcome yet described” for the management of men with clinically localized prostate cancer.
Filed under: Uncategorized | 3 Comments »
A key initiative introduced by Dr. Harold Varmus after he took his current position of Director of the National Cancer Institute (NCI) here in the USA was the “provocative questions” project. His idea was that we should try to identify a small number of really focused questions about cancer and base research funding around seeking [...]
Filed under: Uncategorized | Tagged: provocative, questions, research | Leave a Comment »
The idea that exercise and physicial fitness may be associated with a reduction in risk of disease progression in men with relatively low-risk prostate cancer is hardly new, but
Filed under: Living with Prostate Cancer, Management, Prevention, Uncategorized | Tagged: activity, exercise, low risk, preventiuon, progression | 5 Comments »
According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®).
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: dutasteride, low risk, Prevention, progression | 5 Comments »
Apparently, earlier this week, Congressmen Runyan and Baca (the co-chairmen of the Congressional Prostate Cancer Task Force) sent a letter to Secretary Sebelius about prostate cancer screening.
Filed under: Uncategorized | 3 Comments »
The issue of whether some urology practices are investing in equipment capable of delivering intensity-modulated radiation therapy (IMRT) with financial motives is back on the front burner again.
Filed under: Uncategorized | Tagged: IMRT, motive, profit, radiation therapy, self-referral | 4 Comments »
Published reports on the safety and efficacy of extreme hypofactionated radiation therapy (stereotactic body radiation therapy or SBRT, a.k.a. CyberKnife radiation therapy) have, to date, come from just a couple of key centers.
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: CyberKnife, outcome, SBRT, stereotactic body radiation therapy | 2 Comments »
According to an article in today’s New England Journal of Medicine, a rare but recurrent mutation in a gene known as HOXB13 (rs138213197) — a gene that is important in prostate development — appears to be responsible for early-onset, familial prostate cancer in some men of European descent.
Filed under: Uncategorized | 2 Comments »
A new article in the Canadian Medical Association Journal has reported on a careful analysis of the published literature underlying current guidelines on the use of repetitive PSA testing to monitor risk for progression in men receiving first-line treatment for localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: guideline, monitoring, PSA, recurrence | 3 Comments »
According to a new study published on line in Prostate Cancer and Prostatic Diseases, 370/425 urologists who responded to a recent survey felt that active surveillance was a reasonable management strategy and about 350/425 actually manage patients by using this approach. But
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: acceptance, active surveillance, opinion, urologist | 19 Comments »
The American Cancer Society (ACS) yesterday released projected data for the incidence and the mortality of prostate cancer for 2012. The bottom line: they are projecting more new cases and significantly fewer deaths than in 2011.
Filed under: Uncategorized | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site